PCSK9 deficiency: A double-edged sword?

Abstract

Get full access to this article

View all access options for this article.

References

Seidah

Benjannet

Wickham

et al.

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928–933.

Abifadel

Varret

Rabès

J-P

et al.

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154–156.

Tibolla

Norata

Artali

et al.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure–function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011; 21: 835–843.

Cohen

Pertsemlidis

Kotowski

et al.

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161–165.

Cohen

Boerwinkle

Mosley

et al.

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–1272.

Benn

Nordestgaard

Grande

et al.

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55: 2833–2842.

Sabatine

Giugliano

Keech

et al.

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 2016; 173: 94–101.

Sabatine

Giugliano

Keech

et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Schwartz

Bessac

Berdan

et al.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014; 168: 682–689.

10.

Nicholls

Puri

Anderson

et al.

Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial. JAMA 2016; 316: 2373–2384.

11.

Ray

Landmesser

Leiter

et al.

Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017; 376: 1430–1440.

12.

Landlinger

Pouwer

Juno

et al.

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J 2017; 38: 2499–2507.

13.

Giugliano

Mach

Zavitz

et al.

Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017; 377: 633–643.

14.

Poirier

Mayer

Benjannet

et al.

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008; 283: 2363–2372.

15.

Ouchi

. Adipocytokines in cardiovascular and metabolic diseases. J Atheroscler Thromb 2016; 23: 645–654.

16.

Ouchi

Ohishi

Kihara

et al.

Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231–234.